| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40ea83b496d8918ef0eb0c58ffc217cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d906a69eb4fe05e4e25d24aa6d3d7948
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2f0e6705fcaedd97bed883d5c01a0ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3db54774a9ac326839baf37145ce3e6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff81a650b70e913d3b2524b45e4c7320
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_818ea0bfdc425a6ff3d4e9cf108d490f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2015-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49e2180638a4208f16118e6346aef962
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5287d4956989e6d58b46605f0d2c318
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_566199dfc5e65dd3d91b7fd348d327eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_179e80a2b719b58d36d96e2b99bb4f80 |
| publicationDate |
2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016213638-A1 |
| titleOfInvention |
Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances |
| abstract |
The present invention provides a method of inhibiting the growth of or promoting differentiation and destruction of cancer stem cells (CSCs) comprising contacting the cancer stem cells with a compound having the structure: n n n n n n n n n n or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2012-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |